Promising drug for rare nerve disease trial pulled before start
NCT ID NCT07191912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test whether the drug govorestat could improve symptoms of Charcot-Marie-Tooth disease caused by sorbitol dehydrogenase deficiency (CMT-SORD), a rare nerve condition. It planned to enroll people aged 16 to 65 and compare govorestat to a placebo over 36 months. However, the trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
govorestat (AT-007)
What this could lead to
If it works, this could point toward a treatment that slows or improves symptoms of CMT-SORD, a rare nerve disease.
What could go wrong
This trial was withdrawn before any participants enrolled, so no results are available. The drug is still in early testing, and its benefits and risks are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU La Timone
Marseille, 13005, France
-
Carlo Besta Neurological Institute
Milan, 20133, Italy
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Clinic for Special Children
Gordonville, Pennsylvania, 17529, United States
-
Institut de Myologie
Paris, 75013, France
-
Istanbul University
Istanbul, 34093, Turkey (Türkiye)
-
Koç University Hospital
Istanbul, 34010, Turkey (Türkiye)
-
La Fe University and Polytechnic Hospital
Valencia, 46026, Spain
-
Sydney Childrens
Sydney, 2013, Australia
-
Uniklinik of the RWTH Aachen University
Aachen, 52074, Germany
-
University Medicine Gottingen (UMG)
Göttingen, 37075, Germany
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Vall d'Hebron Institut de Recerca (VHIR)
Barcelona, 08035, Spain